Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) EBIT (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed EBIT for 11 consecutive years, with -$78.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT fell 194.19% to -$78.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$143.4 million, a 226.69% decrease, with the full-year FY2025 number at -$143.4 million, down 226.69% from a year prior.
  • EBIT was -$78.6 million for Q4 2025 at Cartesian Therapeutics, down from -$21.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $13.9 million in Q2 2022 to a low of -$78.6 million in Q4 2025.
  • A 5-year average of -$13.2 million and a median of -$13.2 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: surged 2966.37% in 2022, then plummeted 717.07% in 2023.
  • Cartesian Therapeutics' EBIT stood at $4.1 million in 2021, then tumbled by 308.34% to -$8.5 million in 2022, then plummeted by 327.64% to -$36.3 million in 2023, then rose by 26.43% to -$26.7 million in 2024, then tumbled by 194.19% to -$78.6 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's EBIT are -$78.6 million (Q4 2025), -$21.1 million (Q3 2025), and -$21.8 million (Q2 2025).